Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Grischke

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1996
[Change in the spectrum of uterus-preserving myoma operations including endoscopy and dual myoma therapy]D Wallwiener, B Aydeniz, S Rimbach, et al.
Der Pathologe|September 28, 2000
[Acardius or "twin-reversed arterial prefusion" sequence. Report of four cases and review of current therapeutic possibilities]C Sergi, E M Grischke, P A Schnabel, et al.
Zentralblatt Fur Gynakologie|January 1, 1996
[Laparoscopy in (apparently) benign ovarian tumors between benefit and catastrophy and the deceptive safety of laparoscopic lap sacs]D Wallwiener, I J Diel, C Sohn, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 22, 1999
Reduction of aseptic measures in gynecologic endoscopy: a comparative clinical trialB Aydeniz, A Meyer, H K Geiss, et al.
Archives of Gynecology and Obstetrics|February 4, 2026
Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface areaA Englisch, K Eissler, D Dannehl, et al.
Journal of Cancer Research and Clinical Oncology|November 23, 2011
Nodal status--its impact on prognosis in advanced ovarian cancerC Bachmann, S Bachmann, T Fehm, et al.
International Journal of Cancer|June 8, 2001
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patientsA Seute, H P Sinn, R F Schlenk, et al.
Archives of Gynecology and Obstetrics|April 21, 2026
The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia: a retrospective cohort studyK Eissler, T Engler, D Dannehl, et al.
Stem Cells (Dayton, Ohio)|March 10, 2001
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancerA Schneeweiss, M Hensel, R Goerner, et al.
Gynecologic Oncology|May 23, 2017
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trialC Dinkic, M Eichbaum, M Schmidt, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1996
[Change in the spectrum of uterus-preserving myoma operations including endoscopy and dual myoma therapy]D Wallwiener, B Aydeniz, S Rimbach, et al.
Der Pathologe|September 28, 2000
[Acardius or "twin-reversed arterial prefusion" sequence. Report of four cases and review of current therapeutic possibilities]C Sergi, E M Grischke, P A Schnabel, et al.
Zentralblatt Fur Gynakologie|January 1, 1996
[Laparoscopy in (apparently) benign ovarian tumors between benefit and catastrophy and the deceptive safety of laparoscopic lap sacs]D Wallwiener, I J Diel, C Sohn, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 22, 1999
Reduction of aseptic measures in gynecologic endoscopy: a comparative clinical trialB Aydeniz, A Meyer, H K Geiss, et al.
Archives of Gynecology and Obstetrics|February 4, 2026
Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface areaA Englisch, K Eissler, D Dannehl, et al.
Journal of Cancer Research and Clinical Oncology|November 23, 2011
Nodal status--its impact on prognosis in advanced ovarian cancerC Bachmann, S Bachmann, T Fehm, et al.
International Journal of Cancer|June 8, 2001
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patientsA Seute, H P Sinn, R F Schlenk, et al.
Archives of Gynecology and Obstetrics|April 21, 2026
The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia: a retrospective cohort studyK Eissler, T Engler, D Dannehl, et al.
Stem Cells (Dayton, Ohio)|March 10, 2001
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancerA Schneeweiss, M Hensel, R Goerner, et al.
Gynecologic Oncology|May 23, 2017
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trialC Dinkic, M Eichbaum, M Schmidt, et al.
Pageof 7